Back to results
US 9,801,937 B1Granted
Method for targeting antigens unique to a tumor
AssigneeDartmouth-Hitchcock Clinic
InventorEric R. Henderson
Life of this patent
Estimating the term…
Abstract
A method and system for targeting antigens unique to a tumor site. The method can include a first phase of monoclonal antibodies that bind to the tumor site. A second phase of monoclonal antibodies can be administered that bind to the first phase. A third phase of monoclonal antibodies can be administered that bind to the second phase. The third phase can include radionuclides to allow the tumor site to be imaged. Once identified, a phase of toxins can be administered, resulting in death of the tumor cells.
Claims11
A method of administering multi-phase monoclonal antibody (MAB) therapy to a human patient, comprising:
- identifying a plurality of antigens present in a tumor site of a human patient;
- administering a first plurality of monoclonal antibodies (MABs), the first plurality of monoclonal antibodies comprising a first MAB configured to bind to a first antigen of the first plurality of antigens and a second MAB configured to bind to a second antigen of the first plurality of antigens;
- administering a second plurality of MABs, each of the second plurality of MABs configured to bind to both the first MAB and the second MAB and having an identifier site comprising a unique antigen not native in the human body;
- and
- administering a third plurality of MABs, each of the third plurality of MABs configured to bind to the unique antigen.
2 more elements
Dependencies are inferred from the claim text.